Hikma agrees to acquire the Egyptian Company for Pharmaceuticals & Chemical Industries, strengthening its position in the large and fast growing Egyptian market

London, 9 January 2013 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) ("Hikma"), the fast growing multinational pharmaceutical group, today announces that it has agreed to acquire the Egyptian Company for Pharmaceuticals & Chemical Industries ("EPCI") from a consortium of shareholders. Hikma will pay an aggregate cash consideration of EGP 142.4 million upon closing, or approximately USD 22.2 million, based on the current exchange rate.1

Press Release Corporate 9 January 2013

The acquisition of EPCI:

  • Strengthens Hikma’s position in the large and fast growing Egyptian market
  • Adds a complementary portfolio of 35 products2 in 46 dosage forms and strengths, including 3 original cephalosporin anti–infective brands for the Egyptian market
  • Enhances Hikma’s portfolio in key therapeutic areas such as cephalosporin anti–infectives, central nervous system and alimentary tract and provides entry into the ophthalmology market
  • Adds a dedicated cephalosporin facility and an additional general formulation manufacturing plant in Egypt
  • Leverages Hikma’s established market position in Egypt and strong sales and marketing team
  • The Egyptian pharmaceutical market is one of the largest and fastest growing MENA markets.
  • According to IMS Health,3 the private retail market is valued at around $2.3 billion and grew by 10.6% in the twelve months to June 2012. With a population of approximately 844 million people, the Egyptian market offers excellent growth opportunities. Hikma Egypt is currently the seventeenth largest pharmaceutical manufacturer in Egypt, with an estimated market share of 1.6%.5

Commenting on the transaction, Said Darwazah, CEO of Hikma said, "Since we entered the Egyptian market in 2007, we have been rapidly growing our presence. This acquisition will further accelerate that growth, expanding our product portfolio and adding additional manufacturing capacity and technologies. We continue to strengthen our position as the leading regional manufacturer in MENA and to pursue other value–creating acquisition opportunities in the region."

Closing is expected to occur before February 14th 2013 and is conditional on fulfillment of conditions precedent.

HC Securities and Investment, the Cairo–based investment bank, acted as advisor to Hikma on this acquisition.

The actual US dollar cash consideration will depend on the US dollar/ Egyptian Pound exchange rate on the date of closing 
EPCI has a portfolio of 35 products, of which 27 are new products to Hikma Egypt.

IMS Health MAT 06/2012
The CIA World Factbook, July 2012 estimate
IMS Health YTD 06/2012

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.